Estrogens and cell-cycle regulation in breast cancer

Trends in Endocrinology and Metabolism

Volumn 12, Issue 7, 2001, Pages 320-327

  Foster, James S ^a   Henley, Donald C ^a   Ahamed, Shamila ^a   Wimalasena, Jay ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLINE; ESTRADIOL; ESTROGEN; PROTEIN SERINE THREONINE KINASE;

BREAST TUMOR; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; CYCLINS; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; PROTEIN-SERINE-THREONINE KINASES;

EID: 0035463891     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00436-2     Document Type: Review

References (84)

1. Cummings, S.R. et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197
2. Fisher, B. et al. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388
3. Jordan, V.C. and Morrow, M. (1999) Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev. 20, 253-278
4. Powles, T et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101
5. Veronesi, U. et al. (1998) Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352, 93-97
6. Hofseth, L.J. et al. (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab 84, 4559-4565
7. Sutherland, R.L. et al. (1992) Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists. J. Steroid Biochem. Mol. Biol 41, 315-321
8. Dickson, R.B. and Lippman, M.E. (1995) Growth factors in breast cancer. Endocr. Rev. 16, 559-589
9. Musgrove, E.A. et al. (1994) Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. U. S. A. 91, 8022-8026
10. Wilcken, N.R. et al. (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res. 3, 849-854
11. Leung, B.S. and Potter, A.H. (1987) Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population. J. Cell. Biochem. 34, 213-225
12. Altucci, L. et al. (1996) 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12, 2315-2324
13. Foster, J.S. and Wimalasena, J. (1996) Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10, 488-498
14. Dubik, D. and Shiu, R.P. (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7, 1587-1594
15. Prall, O.W.J. et al. (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association withcyclin E-Cdk2. J. Biol. Chem. 272, 10882-10894
16. Ahamed, S. et al. (2001) Signal transduction through the Ras/Erk pathway is essential for the mycoestrogen zearalenone-induced cell-cycle progression in MCF-7 cells. Mol. Carcinog. 30, 88-98
17. Prall, O.W. et al. (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell. Biol. 18, 4499-4508
18. Charpentier, A.H. et al. (2000) Effects of estrogen on global gene expression. Cancer Res. 60, 5977-5983
19. Chen, I. et al. (2001) Identification of estrogen-induced genes downregulated by AhR agonists. Gene 262, 207-214
20. Bouchard, C. et al. (1998) Control of cell proliferation by Myc. Trends Cell Biol. 8, 202-206
21. Alevizopoulos, K. et al. (1997) Cyclin E and c-Myc promote cell proliferation in the presence of p161NK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 16, 5322-5333
22. Haas, K. et al. (1997) Mutual requirement of CDK4 and Myc in malignant transformation: Evidence for cyclinD1/CDK4 and p16INK4A as upstream regulators of Myc. Oncogene 15, 179-192
23. Leone, G. et al. (1997) Myc and Ras collaborate in inducing accumulation of active cyclin E-Cdk2 and E2F [erratum in Nature 387, 932]. Nature 387, 422-426
24. Bouchard, C. et al. (1999) Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18, 5321-5333
25. Perez-Roger, I. et al. (1999) Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21 (Cip1). EMBO J. 18, 5310-5320
26. Mateyak, M.K. et al. (1999) c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol. Cell. Biol. 19, 4672-4683
27. Beier, R. et al. (2000) Induction of cyclin E-Cdk2 kinase activity, E2F-dependent transcription and cell growth by myc are genetically separable events. EMBO J. 19, 5813-5823
28. Berns, K. et al. (2000) p27kip1-independent cell cycle regulation by MYC. Oncogene 19, 4822-4827
29. Berns, K. et al. (2000) A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts. Oncogene 19, 3330-3334
30. Santoni-Rugiu, E. et al. (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol. Cell. Biol. 20, 3497-3509
31. Obaya, A.J. et al. (1999) Mysterious liaisons: The relationship between c-Myc and the cell cycle. Oncogene 18, 2934-2941
32. Claassen, G.F. and Hann, S.R. (1999) Myc-mediated transformation: The repression connection. Oncogene 18, 2925-2933
33. Cole, M.D. and McMahon, S.B. (1999) The Myc oncoprotein: A critical evaluation of transactivation and target gene regulation. Oncogene 18, 2916-2924
34. Greasley P.J. et al. (2000) Myc induces the nucleolin and BN51 genes: Possible implications in ribosome biogenesis. Nucleic Acids Res. 28, 446-453
35. O'Hagan, R.C. et al. (2000) Myc-enhanced expression of Cull promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 14, 2185-2191
36. Foster, J.S. et al. (2001) Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclinD1-Cdk4 function. Mol. Cell. Biol. 21, 794-810
37. Nielsen, N.H. et al. (1997) Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14, 295-304
38. Said, T.K. et al. (1997) Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 138, 3933-3939
39. Altucci, L. et al. (1997) Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 138, 978-984
40. Geum, D. et al. (1997) Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: Differential induction mechanism of cyclin D1 and D3. Mol. Reprod. Dev. 46, 450-458
41. Tong, W. and Pollard, J.W. (1999) Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol. Cell. Biol. 19, 2251-2264
42. Dees, C. et al. (1997) Dietary estrogens stimulate human breast cells to enter the cell cycle. Environ. Health Perspect. 105 Suppl. 3, 633-636
43. Planas-Silva, M.D. and Weinberg, R.A. (1997) Estrogen-dependent cyclin E-Cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17, 4059-4069
44. Sabbah, M. et al. (1999) Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U. S. A. 96, 11217-11222
45. Planas-Silva, M.D. et al. (1999) Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression. Cancer Res. 59, 4788-4792
46. Webb, P. et al. (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9, 443-456
47. Kushner, P.J. et al. (2000) Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317
48. Bortner, D.M. and Rosenberg, M.P. (1997) Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol. 17, 453-459
49. Nielsen, N.H. et al. (1996) Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer 74, 874-880
50. Geng, Y. et al. (1999) Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97, 767-777
51. Roberts, J.M. (1999) Evolving ideas about cyclins. Cell 98, 129-132
52. Nielsen, N.H. et al. (1999) G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res. Treat. 56, 105-112
53. Loden, M. et al. (1999) Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18, 2557-2566
54. Lukas, J. et al. (1996) Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16, 6917-6925
55. Xu, L. et al. (1994) Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 54, 5262-5264
56. Musgrove, E.A. et al. (1995) Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int. J. Cancer 63, 584-591
57. Saha, P. et al. (1997) p21CIP1 and Cdc25A: Competition between an inhibitor and an activator of cyclin-dependent kinases. Mol. Cell. Biol. 17, 4338-4345
58. Wang, W. et al. (1998) Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: Modulation of hormone-induced cell cycle enzymes. Arch. Biochem. Biophys. 356, 239-248
59. Galaktionov, K. et al. (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382, 511-517
60. Chen, X. and Prywes, R. (1999) Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression. Mol. Cell. Biol. 19, 4695-4702
61. Iavarone, A. and Massague, J. (1999) E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol. Cell. Biol. 19, 916-922
62. Vigo, E. et al. (1999) CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell. Biol. 19, 6379-6395
63. Blomberg, I. and Hoffmann, I. (1999) Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell. Biol. 19, 6183-6194
64. Sexl, V. et al. (1999) A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene 18, 573-582
65. Hoffmann, I. et al. (1994) Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13, 4302-4310
66. Mochizuki, T. et al. (1999) Physical and functional interactions between pim-1 kinase and Cdc25A phosphatase. Implications for the pim-1-mediated activation of the c- myc signaling pathway. J. Biol. Chem. 274, 18659-18666
67. Galaktionov, K. et al. (1995) Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9, 1046-1058
68. Castoria, G. et al. (1999) Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J. 18, 2500-2510
69. Migliaccio, A. et al. (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol- receptor complex in MCF-7 cells. EMBO J. 15, 1292-1300
70. Migliaccio, A. et al. (1998) Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17, 2008-2018
71. Cangi, M.G. et al. (2000) Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 106, 753-761
72. Sandhu, C. et al. (2000) Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. Oncogene 19, 5314-5323
73. Bartek, J. and Lukas, J. (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490, 117-122
74. Carroll, J.S. et al. (2000) A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem. 275, 38221-38229
75. Reddel, R.R. et al. (1984) Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res. 44, 2398-2405
76. Pacilio, C. et al. (1998) Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone responsive human breast cancer cell growth by antiestrogens. Cancer Res. 58, 871-876
77. Cariou, S. et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97, 9042-9046
78. Catzavelos, C. et al. (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat. Med. 3, 227-230
79. Porter, P.L. et al. (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3, 222-225
80. Fredersdorf, S. et al. (1997) Highlevel expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 94, 6380-6385
81. Chen, X. et al. (2000) Activation of the estrogen-signaling pathway by p21 (WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J. Natl. Cancer Inst. 92, 1403-1413
82. Improta-Brears, T. et al. (1999) Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. U. S. A. 96, 4686-4691
83. Lobenhofer, E.K. et al. (2000) Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 11, 99-110
84. Levin, E.R. (1999) Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol. Metab 10, 374-377